

EPEC training of trainers (TOT) index

adult learning, TOT-1
case studies, TOT-12
checklist of tasks, TOT-50
“difficult” participants, TOT-25
facilitating discussions, TOT-15
flipcharts, TOT-21
humor, TOT-25
learning, passive to active, TOT-6
lecture, TOT-10
planning worksheet, TOT-35-37
role play, TOT-14
slide development and use, TOT-52
teaching styles, adult-adult, TOT-5
teaching styles, adult-child, TOT-5
teaching styles, TOT-4
training administration, TOT-41
training methods, TOT-9
video, TOT-20
visual aids, TOT-21

EPEC end-of-life index

A

abandonment, fear of, M5-12
acetaminophen, M4-6
acetylcholine antagonists
 (anticholinergics), M10-13
addiction, M4-10
adjuvant analgesics, M4-17
advance care planning, M1-1, M3-9
advance directives, P2-7, M1-3
advance practical planning, M1-11
advisory document, M1-6, 14
advocacy, P4-3
airway obstruction, M10-31
allergy, M4-20
alprazolam, M6-8
AMA Public Opinion Survey, P1-7
AMA’s Council on Ethical and
 Judicial Affairs, M1-15
amitriptyline, M4-17
androgens, M10-20
anemia, M10-31
anorexia/cachexia, M10-19
antacids, M10-14
anxiety
 anxiety, M6-6
 during ventilator withdrawal, M11-10
anxiolytics, M10-8
appetite/food intake, decreasing, M12-5

artificial feeding and hydration, M11-7, 21
artificial ventilation, M11-22
aspirin, M4-6
assessment
 assessment, M3-2
 of pain, M4-3
attapulgate, M10-18
atypical antidepressants, M6-8
atypical neuroleptics, M6-9

B

Baby Doe regulations, P2-6
barriers
 to end-of-life care, P1-8, P4-4
 to pain management, M4-23
being a burden, fear of, M5-11
benzodiazepines, M6-7, M10-8, M12-9
bereavement, M12-16, 18
bisacodyl, M10-16
bismuth salts, M10-18
bisphosphonates, M4-19
blood perfusion, decreasing, M12-6
bolus effect, M4-13
bone pain, M4-19
Borg Faces Scale, M3-6
bowel obstruction
 cause of nausea, M10-15
 pain from, M4-19
breakthrough dosing, M4-9

breathlessness
 breathlessness, M10-5
 during ventilator withdrawal, M11-10
Brief Pain Inventory (Short Form), M3-6
Brody, Howard, P3-2
bronchospasm, M10-30
butorphanol, M4-10
Byock, Ira, P3-2

C

calcium docusate, M10-16
cannabinoids, M10-20
capacity, M3-8, M8-6
carbamazepine, M4-18
cardiopulmonary resuscitation
 (CPR), M11-13, 23
caregiver
 caregiver, M1-11, M3-14
 sharing of information, M2-8
caregiving, P1-5
casanthranol, M10-16
Cassell, Eric, P3-1
chlorpromazine, M6-9
cisapride, M10-14, 17
clearance, M4-9
clonazepam, M6-7, M10-8
closing eyes, loss of ability, M12-12
codeine, M4-7
common law, P2-2
communication
 communication, M3-9
 of bad news, M2-1
 with the unconscious patient, M12-8
community, M3-10
confidentiality, P2-10
conflict, over treatment, M9-3
conjunctival care, M12-6
consciousness, decreasing level of, M12-8
consequences, intended vs unintended, M10-3
constipation, M4-21, M10-15
control, loss of, M5-10
coping strategies, P1-5
corticosteroids, M4-19

counseling, M6-4
countertransference, M5-6
Cruzan, P2-4
cultural difference, M7-10, M8-8
culture, P3-4
cytoprotective agents, M10-14

D

death, signs of, M12-13
decision making
 decision making, M3-8
 decision-making capacity, P2-5, M7-13
 surrogate, P2-4
decline oral intake, M5-13
dehydration, M12-5
delirium, M4-22, M6-8
depression, M5-6, M6-2
desipramine, M4-17
detergent laxatives, M10-16
dexamethasone, M10-15, 20, 21
dezocine, M4-10
diarrhea, M10-18
diazepam, M6-7, M10-8
diphenhydramine, M10-13
diphenoxylate/atropine, M10-18
distrust, M9-6
do not intubate (DNI), M11-16
do not resuscitate (DNR), M11-14
do not transfer, M11-16
documentation, M1-7
domestic needs, M3-15
“don’t tell”, M2-4
dopamine antagonists, M10-13
double effect, principle of, P2-8, M10-4
droperidol, M10-13
Drug Enforcement Agency, P2-8
durable power of attorney for health
 care, P2-7, M1-3
dying
 dying, M11-8
 trajectories, P1-2
dyspnea, M10-5

E

edema, M10-22
emotional responses, M3-6
emotions, M11-6
end-of-life experience, P3-3
enemas, M10-17
EPEC themes, P4-1
equianalgesic table, M4-13
ethics committees, P2-10
ethnicity, P3-4
euthanasia, M5-1, M11-3
expected death, M12-13
extended-release opioids, M4-8

F

families, P4-3
family issues, M9-7
family, M3-15
fatigue, M10-21, M12-4
fears
 addressing, M5-10
 fears, M3-7, M5-7
financial
 financial, M3-11
 pressures, P1-5
first-pass metabolism, M4-13
function, M3-6
futility, P2-9, M9-1

G

gabapentin, M4-18
Gallup survey, P1-6
gaps, P1-7
glycerin suppositories, M10-17
goals of care, M3-9, M7-2, M8-5
goals of EPEC, P1-8
granisestron, M10-14
grief
 complicated, M12-19
 grief, M9-7, M12-18
 normal, M12-18
guardianship, P2-6

guilt, M9-7

H

H₂ receptor antagonists, M10-14
haloperidol, M6-9, M10-13
health care proxy, M1-3
histamine antagonists (antihistamines), M10-13
historical perspective, P1-1
hope
 expectations, P3-6
 hope, M7-9
hospice, P1-6, P3-10
hydrocodone, M4-7
hydromorphone, M4-7, M10-8
hydroxyzine, M10-13

I

immediate extubation, M11-9
immediate-release opioids, M4-8
incompetence, P2-5
indignity, fear of, M5-12
informed consent, P2-2, M8-6, M11-6
insomnia, M10-25
instructional directives, M1-3
International Association for the Study
 of Pain (IASP), M4-3

J

Joint Commission on Accreditation of
 Healthcare Organizations (JCAHO), P2-2

L

lactulose, M10-16
language, M2-7, M7-10
last hours
 of life, preparation for, M1-10
 of living, M12-1
legal counsel, P2-10
life expectancy, P1-1
life-sustaining treatments, M11-3
living will, P2-7, M1-3
lorazepam, M6-7, M10-8, 15
loss, M12-18

lubricant stimulants, M10-17

M

magnesium citrate, M10-16
meaning and value, M7-2
meaning of illness, M3-12
meclizine, M10-13
medical directive, M1-3
medical futility, M9-1
megestrol acetate, M10-20
Memorial Symptom Assessment Scale, M3-6
meperidine, M4-10
methadone, M4-9
methylphenidate, M10-22
metoclopramide, M10-13, 14, 16
midazolam, M10-8
milk of magnesia, M10-16
miracles, M9-9
misoprostol, M10-14
models for care, P3-9
morphine, M4-7, M10-8
mucosal care, M12-6

N

nalbuphine, M4-10
nausea/vomiting
 nausea/vomiting, M4-21, M10-9
 pathophysiology of, M10-10
neurological dysfunction, M12-6
neuropathic pain, M4-3, 17
NMDA receptor antagonists, M4-18
nociceptive pain, M4-3
nonpharmacologic
 interventions
 for breathlessness, M10-8
 management
 of anxiety, M6-7
 of depression, M6-6
 of pain, M4-23
nonsteroidal anti-inflammatory drugs
 (NSAIDs), M4-6
normeperidine, M4-10
nortriptyline, M4-17

O

octreotide, M10-15, 19
odors, M10-25
oils, M10-17
olanzepine, M6-9
ondansetron, M10-14
opioids
 adverse effects, M4-20
 allergy, M4-20
 alternate routes of administration, M4-12
 changing routes of administration, M4-13
 changing, M4-14
 cross-tolerance, M4-14
 dosing, M4-8
 intraspinal, M4-13
 opioids, P2-8
 parenteral, M4-12
 pharmacology, M4-7
 to manage breathlessness, M10-7
 transdermal, M4-12
 transmucosal, M4-12
osmotic laxatives, M10-16
outcomes, P3-9
oxazepam, M6-8
oxycodone, M4-7, M10-8
oxygen, M10-6

P

pain
 assessment, M3-4
 fear of, M5-11
 in the last hours, M12-11
 pain, M4-1
palliative care, P1-6, P3-11, P4-2, M7-7
pastors, M3-13
pathophysiology, M4-3
Patient Self-Determination Act, P2-7, M1-15
pentazocine, M4-10
perphenazine, M10-13
phosphosoda enema, M10-16

physical
 addressing suffering, M5-9
 assessment, M3-3
 dependence, M4-10
 suffering, M5-7
 Physician Orders for Life-Sustaining Treatment (POLST), M11-16
 physician training, P1-7
 physician-assisted suicide, P2-8, M5-1
 physiologic changes of dying, M12-4
 place of death, P1-6
 placebos, M4-4
 planning for death, M3-15
 pleural effusion, M10-31
 practical
 addressing concerns, M5-8
 assessment, M3-14
 concerns, M5-7
 prayers, M3-13
 pressure ulcers, M10-25
 prochlorperazine, M10-13
 prognosis
 communicating, M2-7, M7-8
 conflict over misunderstanding, M9-4
 prokinetic agents, M10-14, 16
 promethazine, M10-13
 propoxyphene, M4-10
 proton pump inhibitors, M10-14
 proxy, role of, M1-5
 prune juice, M10-16
 pruritus, M4-21
 psychological
 addressing suffering, M5-8
 assessment, M3-6
 psychosocial, suffering, M5-7
 psychostimulants
 for treatment of depression, M6-5
 for treatment of fatigue/weakness, M10-22
 public expectations, P1-7

Q

quetiapine, M6-9

R

race, P3-4
 reactions to bad news, M2-5
 regulatory law, P2-2
 religious beliefs, M9-9
 renal failure, M12-6
 respiration, changes in the dying
 patient, M12-10
 respiratory depression, M4-22
 risperidone, M6-9
 rituals, M3-13

S

satisfaction, P3-9
 Saunders, Cicely, P3-3
 scopolamine, M10-13, M12-10
 secondary gain, M9-8
 sedation, M4-22, M5-14
 selective serotonin reuptake inhibitors (SSRIs), M6-5
 senna, M10-16
 serotonin antagonists, M10-14
 setting of care, M1-11
 severity, M3-5
 skin care, M10-24
 social
 addressing suffering, M5-8
 assessment, M3-10
 isolation, P1-5
 sodium docusate, M10-16
 sphincter control, loss of, M12-11
 spiritual
 addressing suffering, M5-10
 assessment, M3-11
 spiritual, P3-7
 suffering, M5-7
 standards, hospice and palliative care, P3-13
 statutory documents, M1-7
 statutory law, P2-2
 stimulant laxatives, M10-16
 stool softeners, M10-16
 stress, impact on professionals, M8-9

substance abuse, M4-11
sudden illness, M8-1
suffering, conceptions of, P3-2
suicide, M6-3
support, personal, P4-5
surrogate
 selection, M9-4
 surrogate, P2-7
swallow, loss of ability, M12-10
symptoms
 assessment, M3-3
 fear of, M5-11
 frequency, P1-4
 management, M8-8
 symptoms, M10-1

T

teamwork, P4-3
terminal delirium, M12-8
terminal weaning, M11-10
tetrahydrocannabinol (THC), M10-20, 15
thick secretions, M10-30
thiethylperazine, M10-13
time-limited trials, M8-7
tincture of opium, M10-18
tolerance, M4-10
topical analgesia, M4-20
translator, M2-7
treatment limitations, P2-4
treatment priorities, M7-11
tricyclic antidepressants, M4-17, M6-6
trimethobenzamide, M10-13
truth-telling, M7-9
two roads to death, M12-7

U

uncertainty, M8-4
unresolved issues, M3-7
urticaria, M4-21

V

valproic acid, M4-18

values
 difference in, M9-9
 history, M1-3
 of life, M9-10
ventilator withdrawal, M11-9

W

wasting, M12-5
weakness, M10-21, M12-4
WHO 3-step ladder, M4-5
withdrawal of treatment, M5-13
withdrawing or withholding
 treatment, P2-4, M11-1
worksheet, M1-6